Cardiovascular safety of celecoxib (Celebrex)
admin December 19th, 2004
Pfizer has released information from two long term trials of celecoxib in cancer patients. One of the trials showed an increased cardiovascular risk over placebo.
Pfizer’s statement
FDA statement
MHRA statement
EMEA’s press release
ADRAC media statement